Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 7 - Drugs for disorders of the blood or the extracellular fluid
Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
06/2003
06/19/2003WO2003049737A1 Chemical compounds
06/19/2003WO2003049735A1 Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders
06/19/2003WO2003049717A2 Conductance of improperly folded proteins through the secretory pathway and related treatments of diseases
06/19/2003WO2003049694A2 Methods of therapy for non-hodgkin's lymphoma
06/19/2003WO2003049686A2 Stabilization of hypoxia inducible factor (hif) alpha
06/19/2003WO2003009777A3 Delivery of therapeutic capable agents
06/19/2003WO2002060434A3 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
06/19/2003WO2002051429A3 Use of a composition for the stimulation of nerve growth, the inhibition of scar tissue formation, the reduction of secondary damage and/or the accumulation of macrophages
06/19/2003WO2002029058A3 Human proteins, polynucleotides encoding them and methods of using the same
06/19/2003US20030114683 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors
06/19/2003US20030114678 Cardioprotective phosphonates and malonates
06/19/2003US20030114677 Cardioprotective phosphonates and malonates
06/19/2003US20030114488 New processes for producing beta-alanine derivatives
06/19/2003US20030114478 Asthma therapy; antiinflammatory agents
06/19/2003US20030114457 2- [5- (5-carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors
06/19/2003US20030114448 Inhibitors of factor Xa
06/19/2003US20030114442 Reducing concentration of blood lipoproteins
06/19/2003US20030114416 Analgesics; antiinflammatory, -arthritic agents; vision defects; gastrointestinal and uorgenital disorders; wound healing agents; kits
06/19/2003US20030114372 Isolated DNA encoding amino acid sequences, serine protease inhibitor, host cell transformed with a DNA molecule, Kunitz type Inhibitor, blood coagulation factors
06/19/2003US20030114361 Antithrombotic compound
06/19/2003US20030113890 Nematode-extracted serine protease inhibitors and anticoagulant proteins
06/19/2003US20030113871 Glycoprotein hormones; human chorionic gonadotropin; carboxy terminal peptides (ctp); increaseing half life of polypeptides; antipernicious anemia drugs
06/19/2003US20030113840 25 human secreted proteins
06/19/2003US20030113775 7118, a human arginine N-methyltransferase family member and uses therefor
06/19/2003US20030113707 Erythrocyte transport protein suspension obtained by removing fibrin and separating erythrocytes from hematocrit; storage stability; antihypoxic agents
06/19/2003US20030113704 Viricides; low chloride/hypotonic mixture for destroying blood parasites
06/19/2003US20030113393 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
06/19/2003US20030113366 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
06/19/2003US20030113361 Palatable arginine compounds and uses thereof for cardiovascular health
06/19/2003US20030113359 Prosthetic device placed on the outside surface of the vessel or graft which then elutes antiproliferatives from a matrix
06/19/2003US20030113262 Gpib-lipid bond construct and use thereof
06/19/2003CA2469889A1 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
06/19/2003CA2469679A1 Heme-regulated eukaryotic initiation factor 2 alpha kinase knockout mice and methods for use
06/19/2003CA2469483A1 Hematopoietic cells from human embryonic stem cells
06/19/2003CA2469045A1 Methods of therapy for non-hodgkin's lymphoma
06/19/2003CA2468892A1 Vitamin d analogues
06/19/2003CA2468659A1 Urea substituted imidazopyridines
06/19/2003CA2468174A1 Amide substituted imidazopyridines
06/19/2003CA2468164A1 Sulfonamido substituted imidazopyridines
06/19/2003CA2467689A1 Stabilization of hypoxia inducible factor (hif) alpha using inhibitors of hif prolyl hydroxylase
06/19/2003CA2465759A1 Method for administering birb 796 bs
06/19/2003CA2464341A1 Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
06/18/2003EP1319712A2 Fusion protein having enhanced in vivo activity of erythropoietin
06/18/2003EP1319709A1 Disruption of the glutathione S-transferase-omega-1 gene
06/18/2003EP1319183A2 Methods and products related to low molecular weight heparin
06/18/2003EP1319182A2 G-csf analog compositions and methods
06/18/2003EP1319067A2 Human coagulation factor vii variants
06/18/2003EP1319007A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
06/18/2003EP1319001A1 Pyrazolopyridines and pyrazolopyridazines as antidiabetics
06/18/2003EP1318991A1 Benzoic acid derivatives and uses thereof
06/18/2003EP1318985A2 4-amino-quinazolines
06/18/2003EP1318984A1 4-amino-quinazolines
06/18/2003EP1318977A1 Substituted phenylcyclohexane carboxylic acid amides and the use thereof
06/18/2003EP1318840A2 PHOSPHATONIN-RELATED GENE AND i METHODS OF USE THEREOF /i
06/18/2003EP1318827A1 Polymer-modified synthetic proteins
06/18/2003EP1318809A1 Micronized torsemide
06/18/2003EP1318804A1 Iron compositions
06/18/2003EP1255757B1 Amino acid derivatives and use thereof as nep, ace and ece inhibitors
06/18/2003CN1425024A Haemostatically active preparation containing VWF and production thereof
06/18/2003CN1424915A Oral, nasal and pulmonary dosage formulations of copolymer1
06/18/2003CN1424910A IL-8 receptor antagonists
06/18/2003CN1424319A Extracts of cornus officinalis and its preparation and use
06/18/2003CN1424091A External applied medicinal liquor for treating angitis and production thereof
06/18/2003CN1424083A Medicine for thrombotic diseases
06/18/2003CN1424080A Medicine for acute cerebral hemorrhage and its preparing method
06/18/2003CN1111357C Food products having enhanced cocoa polyphenol content and processes for producing same
06/17/2003US6579978 Biomaterials comprising N-sulphated hyaluronic acid compounds or derivatives thereof
06/17/2003US6579879 For therapy of diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic cardiomyopathy, diabetic microangiopathy and diabetic macroangiopathy in mammals
06/17/2003US6579874 Substituted azoles
06/17/2003US6579858 Use of low-molecular-weight heparins for the prevention and treatment of cerebral edemas
06/17/2003US6579723 Method of recovering highly purified vWF or factor VIII/vWF-complex
06/17/2003CA1341432C Variants of plasminogen activators and processes for their production
06/12/2003WO2003048210A1 Fusion protein having enhanced in vivo erythropoietin activity
06/12/2003WO2003048205A2 Novel proteins with il-6 inhibiting activity
06/12/2003WO2003048180A1 Crystalline form of a ribofuranosyluronamide derivative; a human adenosine a2a receptor agonist
06/12/2003WO2003048160A1 Ring fused pyrazole derivatives
06/12/2003WO2003048158A1 Glycinamides as factor xa inhibitors
06/12/2003WO2003048155A1 Thrombin inhibitors
06/12/2003WO2003048120A2 2-aryl pyrrologpyrimidines for a1 and a3 receptors
06/12/2003WO2003048081A2 Glycinamides as factor xa inhibitors
06/12/2003WO2003047627A1 Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a thiazolidinedione derivative, and a use thereof for treating diabetes
06/12/2003WO2003047620A2 Compositions and methods for producing vascular occlusion
06/12/2003WO2003047597A1 Combination of crystalline form of a ribofuranosyluronamide derivative and tiotropium salt
06/12/2003WO2003047566A1 Use of coumarin or its hydroxy derivative for the treatment of medium or severe vascular and/or lymphatic edema
06/12/2003WO2003047554A1 Transdermal drug delivery system of strychnine, brucine, securinine and their salts
06/12/2003WO2003047530A2 Storage-stable fibrin sealant
06/12/2003WO2003047520A2 SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS
06/12/2003WO2003047517A2 Novel-n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1-h-pyrazole-5-carboxamides as factor xa
06/12/2003WO2003047507A2 Factor viii c2 domain variants
06/12/2003WO2003027282A9 Adamts-15, -16, -17, -18 and -19
06/12/2003WO2003016273A3 Peptide arginals and methods for treating disseminated intravascular coagulation
06/12/2003WO2002103031A3 Methods for detecting and treating the early onset of aging-related conditions
06/12/2003WO2002000192A8 Embolization using carbon coated particles
06/12/2003US20030109813 Energy-activated targeted cancer therapy
06/12/2003US20030109715 3,4-Dihydro-1H-naphthalene derivatives as a highly selective cyclooxygenase-2 inhibitor
06/12/2003US20030109587 Gelling composition
06/12/2003US20030109570 Activate a peroxisome proliferator-activated receptor (PPAR) alpha or gamma which is an intranuclear transcription factor. The compound may be used as an active ingredient to give a drug for preventing or treating a variety of diseases
06/12/2003US20030109569 Amorphous, pharmaceutically acceptable atorvastatin salts, especially the calcium salt, are prepared from atorvastatin lactone or from a compound of formula (I) mixture of amorphous and crystalline forms of the atorvastatin salt. HMG-CoA
06/12/2003US20030109556 Melanocortin receptor ligands
06/12/2003US20030109547 Amidinophenylpyruvic acid derivatives
1 ... 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 ... 671